Tislelizumab in Combination with Investigational Agents as treatment in patients with Head & Neck Ca

A Randomized, Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination with Investigational Agents as First-Line Treatment in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (BGB-HNSCC-201)

Disease Types: Head and Neck

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

A Randomized, Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination with Investigational Agents as First-Line Treatment in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (BGB-HNSCC-201)

For More Information:

https://clinicaltrials.gov/study/NCT05909904?term=%09NCT05909904&rank=1